✨ Free AI Report
KYORIN Pharmaceutical Co., Ltd.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research KYORIN Pharmaceutical Co., Ltd.
Company Research

KYORIN Pharmaceutical Co., Ltd.: Business Overview, Financials & Competitive Analysis

KYORIN Pharmaceutical manufactures pharmaceuticals and medical products, producing and distributing prescription medicines, quasi-drugs, diagnostic drugs, medical tools, medical equipment, health foods, cosmetics, and...

Analyst-debate audio for KYORIN Pharmaceutical Co., Ltd.

AskCyborg analysts argue the bull and bear cases for KYORIN Pharmaceutical Co., Ltd. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
5/ 10Mixed

Cyborg Score thesis

Mature dividend-paying pharma company with declining earnings facing restructuring pressures in competitive generic and specialty...

Read the full analyst-debate transcript →
Industry Pharmaceuticals & Biotech
3 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest KYORIN Pharmaceutical Co., Ltd. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

KYORIN Pharmaceutical Co., Ltd. Overview

Pro stress-test →

KYORIN Pharmaceutical manufactures pharmaceuticals and medical products, producing and distributing prescription medicines, quasi-drugs, diagnostic drugs, medical tools, medical equipment, health foods, cosmetics, and other products. Through its subsidiaries, the company researches, develops, manufactures, and sells ethical and generic drugs in Japan and internationally.

Strategic Profile

Pro stress-test →

The company offers a portfolio of specialty therapeutics including Flutiform (asthma), Pentasa (ulcerative colitis/Crohn's disease), and Nasonex (allergic rhinitis), alongside diagnostics and contract manufacturing services. KYORIN has development and commercialization agreements with innovators like Hyfe Inc. for digital therapeutics focused on chronic cough.

Competitive Landscape

Pro stress-test →

KYORIN competes in Japan's fragmented pharmaceutical market against larger global players (Takeda, Daiichi Sankyo, Astellas) and generic manufacturers. The company's focus on specialty therapeutics and licensing partnerships provides differentiation, though scale disadvantages persist in competing for blockbuster drugs.

Industry Context

KYORIN Pharmaceutical Co., Ltd. operates in Pharmaceuticals & Biotech.

Key facts

Founded: 1923 · Headquarters: Tokyo, Japan · Employees: 2,000 · Revenue: Not available in search results · Market cap: ¥88.53B (~$600M USD equivalent)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on KYORIN Pharmaceutical Co., Ltd..

  • Market capitalization is approximately ¥88.53 billion
  • The company maintains a ¥32.00 dividend yield of 3.8%
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2025Affirmed dividend of ¥32.00 per share with 3.8% dividend yield
  • June 2024Entered licensing agreement with Almirall for COPD drug aclidinium bromide exclusive rights in Japan
Get alerted when KYORIN Pharmaceutical Co., Ltd. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Ethical/Generic PharmaceuticalsLarger diversified Japanese pharma with global reach→Specialty PharmaceuticalsJapanese pharmaceutical focusing on oncology and cardiology→Contract Manufacturing/GenericsGlobal generic and biosimilar competitor→

Compare KYORIN Pharmaceutical Co., Ltd. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

KYORIN Pharmaceutical Co., Ltd. operates in Pharmaceuticals & Biotech. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals & Biotech research →
NEW · MCP server

Ask your AI assistant about KYORIN Pharmaceutical Co., Ltd.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare KYORIN Pharmaceutical Co., Ltd. and its top competitor on Cyborg Score”
“What did KYORIN Pharmaceutical Co., Ltd. do this quarter?”
“Is KYORIN Pharmaceutical Co., Ltd. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does KYORIN Pharmaceutical Co., Ltd. do?+
KYORIN Pharmaceutical manufactures pharmaceuticals and medical products, producing and distributing prescription medicines, quasi-drugs, diagnostic drugs, medical tools, medical equipment, health foods, cosmetics, and...
What is KYORIN Pharmaceutical Co., Ltd.'s Cyborg Score?+
KYORIN Pharmaceutical Co., Ltd. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are KYORIN Pharmaceutical Co., Ltd.'s main competitors?+
Named competitors include Ethical/Generic Pharmaceuticals, Specialty Pharmaceuticals, Contract Manufacturing/Generics. The full competitive landscape is in the AskCyborg report.
How can I get the full KYORIN Pharmaceutical Co., Ltd. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the KYORIN Pharmaceutical Co., Ltd. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track KYORIN Pharmaceutical Co., Ltd. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals & Biotech research

Companies in the same sector and named competitors, ranked by Cyborg Score.

4Organon & Co.